NIH: Tenure-Track Investigator, Immunology/Immunotherapy
The Neuro-Oncology Branch (NOB), Center for Cancer Research (CCR) of the National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services (HHS), Bethesda, MD, is actively recruiting for a tenure-track principal investigator to work in the area of immunology and/or immunotherapy. The NOB Immunology/Immunotherapy Investigator will be tasked with forming and leading an independent research program. This position will build the basic immunology program in the NOB and complement ongoing and planned translational research and clinical trials evaluating the effects of immunotherapy in patients with primary brain tumors. This program will be able to access biospecimens generated from ongoing and planned immunotherapy protocols within the NOB, thus creating an opportunity to perform correlative studies to interrogate the complex biology of immunologic response, toxicity, and treatment resistance. Demonstrated expertise in scientific inquiries in immunotherapy and/or immunology are essential, but prior work in brain tumors is not required. This is an exciting opportunity to join a growing trans-institutional research team that promotes and supports collaborations across the basic, translational, and clinical research spectrum to develop novel therapeutics for individuals with primary central nervous system malignancies that will globally influence the field.
About NCI’s Center for Cancer Research
The CCR is an intramural research component of the NCI. The CCR’s enabling infrastructure facilitates clinical studies at the NIH Clinical Center, the world’s largest dedicated clinical research complex; and provides extensive opportunities for collaboration with other investigators at the forefront of medical research. This environment enables scientists and clinicians to undertake high-risk, high-impact, laboratory- and clinic-based investigations. Investigators are supported by a wide array of intellectual, technological, and research resources. This includes surgical and pathology facilities; animal facilities; and dedicated, high-quality technology cores. For an overview of CCR, please visit: http://ccr.cancer.gov/. Access to core research support is also available to NCI CCR investigators through the Office of Science and Technology Resources (OSTR) that identifies, evaluates, and makes available new technologies and scientific resources. For more information of OSTR, please visit: https://ostr.cancer.gov/resources. The NCI Center of Excellence in Immunology (CEI) also provides a network of diverse intellectual, financial, and physical resources to help develop new initiatives, projects, and collaborations. For more information of CEI, please visit: https://ccrod.cancer.gov/confluence/display/COEI/Home.
The NOB also offers collaborative opportunities and resources through its various laboratory programs, encompassing areas of research in cell biology, genomics, and metabolomics, as well as its pre-clinical translational research program. For more information of NOB, please visit: https://ccr.cancer.gov/Neuro-Oncology-Branch.
The successful candidate should have a Ph.D. or equivalent doctoral degree and a well-established track record of publications in the area of immunology/immunotherapy. Candidates will be evaluated on their educational background, scholarly work, leadership and mentoring activities, and experience with immunology/immunotherapy research. Salary is commensurate with education and experience. Candidates may be U.S. citizens, U.S. permanent residents, or eligible for a visa that will enable work in the U.S.
Please submit curriculum vitae and statement of research interests and future plans to: http://irp-positions.nih.gov/job/NOBImmunology. Review of applications will begin on or about July 1, 2018and the position will remain open until filled.
HHS, NIH, and NCI are Equal Opportunity Employers.
The NIH and NCI are dedicated to building a diverse community in its training and employment programs and encourages the application and nomination of qualified women, minorities, and individuals with disabilities.
You may be interested
ESNI – Amsterdam 2019stine - 7 Febbraio 2019
17th European School of Neuroimmunology
ASNI – Montreal 2019stine - 5 Febbraio 2019
3rd Americas School of Neuroimmunology